CN116473234A - Basic formula of low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar and functional food thereof - Google Patents
Basic formula of low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar and functional food thereof Download PDFInfo
- Publication number
- CN116473234A CN116473234A CN202310389155.8A CN202310389155A CN116473234A CN 116473234 A CN116473234 A CN 116473234A CN 202310389155 A CN202310389155 A CN 202310389155A CN 116473234 A CN116473234 A CN 116473234A
- Authority
- CN
- China
- Prior art keywords
- powder
- raw powder
- food
- decoction piece
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 141
- 239000008280 blood Substances 0.000 title claims abstract description 141
- 235000000346 sugar Nutrition 0.000 title claims abstract description 129
- 235000013376 functional food Nutrition 0.000 title claims abstract description 51
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 44
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 41
- 229910052799 carbon Inorganic materials 0.000 title claims abstract description 36
- 230000001276 controlling effect Effects 0.000 title abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 174
- 235000013305 food Nutrition 0.000 claims abstract description 69
- 239000000284 extract Substances 0.000 claims abstract description 46
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 23
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 23
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 23
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 23
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- 210000000582 semen Anatomy 0.000 claims abstract description 22
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 21
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 21
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 21
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 claims abstract description 19
- 229920002752 Konjac Polymers 0.000 claims abstract description 19
- 229920001543 Laminarin Polymers 0.000 claims abstract description 19
- 239000005717 Laminarin Substances 0.000 claims abstract description 19
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 19
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 19
- 244000197580 Poria cocos Species 0.000 claims abstract description 19
- 240000008067 Cucumis sativus Species 0.000 claims abstract description 18
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims abstract description 18
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 18
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 18
- 239000001259 polydextrose Substances 0.000 claims abstract description 18
- 229940035035 polydextrose Drugs 0.000 claims abstract description 18
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 18
- 235000010485 konjac Nutrition 0.000 claims abstract description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 55
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 38
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 38
- 235000005911 diet Nutrition 0.000 claims description 34
- 235000019136 lipoic acid Nutrition 0.000 claims description 31
- 229960002663 thioctic acid Drugs 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 240000001740 Momordica dioica Species 0.000 claims description 22
- 239000008187 granular material Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 240000002624 Mespilus germanica Species 0.000 claims description 20
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 19
- 229930003268 Vitamin C Natural products 0.000 claims description 19
- 229930003427 Vitamin E Natural products 0.000 claims description 19
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 19
- 235000019154 vitamin C Nutrition 0.000 claims description 19
- 239000011718 vitamin C Substances 0.000 claims description 19
- 235000019165 vitamin E Nutrition 0.000 claims description 19
- 229940046009 vitamin E Drugs 0.000 claims description 19
- 239000011709 vitamin E Substances 0.000 claims description 19
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 18
- 239000007901 soft capsule Substances 0.000 claims description 18
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 17
- 235000013399 edible fruits Nutrition 0.000 claims description 17
- 240000007594 Oryza sativa Species 0.000 claims description 16
- 235000007164 Oryza sativa Nutrition 0.000 claims description 16
- 235000009566 rice Nutrition 0.000 claims description 16
- 235000013336 milk Nutrition 0.000 claims description 15
- 239000008267 milk Substances 0.000 claims description 15
- 210000004080 milk Anatomy 0.000 claims description 15
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 14
- 235000013339 cereals Nutrition 0.000 claims description 14
- 235000015872 dietary supplement Nutrition 0.000 claims description 14
- 239000011777 magnesium Substances 0.000 claims description 14
- 229910052749 magnesium Inorganic materials 0.000 claims description 14
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 13
- 235000013793 astaxanthin Nutrition 0.000 claims description 13
- 239000001168 astaxanthin Substances 0.000 claims description 13
- 229940022405 astaxanthin Drugs 0.000 claims description 13
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 13
- 239000004006 olive oil Substances 0.000 claims description 13
- 235000008390 olive oil Nutrition 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 13
- 235000019156 vitamin B Nutrition 0.000 claims description 13
- 239000011720 vitamin B Substances 0.000 claims description 13
- 230000002641 glycemic effect Effects 0.000 claims description 12
- 244000268590 Euryale ferox Species 0.000 claims description 11
- 235000006487 Euryale ferox Nutrition 0.000 claims description 11
- 229910052804 chromium Inorganic materials 0.000 claims description 11
- 239000011651 chromium Substances 0.000 claims description 11
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims description 10
- 244000130270 Fagopyrum tataricum Species 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 10
- 235000013312 flour Nutrition 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- 241000233866 Fungi Species 0.000 claims description 9
- 244000269722 Thea sinensis Species 0.000 claims description 9
- 230000000378 dietary effect Effects 0.000 claims description 9
- 235000021388 linseed oil Nutrition 0.000 claims description 9
- 239000000944 linseed oil Substances 0.000 claims description 9
- 235000010469 Glycine max Nutrition 0.000 claims description 8
- 244000068988 Glycine max Species 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 235000021395 porridge Nutrition 0.000 claims description 8
- 229940045997 vitamin a Drugs 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 240000007049 Juglans regia Species 0.000 claims description 7
- 235000009496 Juglans regia Nutrition 0.000 claims description 7
- 240000002853 Nelumbo nucifera Species 0.000 claims description 7
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 7
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 7
- 240000003829 Sorghum propinquum Species 0.000 claims description 7
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- 235000020235 chia seed Nutrition 0.000 claims description 7
- 235000013330 chicken meat Nutrition 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 235000015277 pork Nutrition 0.000 claims description 7
- 235000019155 vitamin A Nutrition 0.000 claims description 7
- 239000011719 vitamin A Substances 0.000 claims description 7
- 235000020234 walnut Nutrition 0.000 claims description 7
- 241000143060 Americamysis bahia Species 0.000 claims description 6
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 235000013616 tea Nutrition 0.000 claims description 6
- 235000011194 food seasoning agent Nutrition 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 240000007124 Brassica oleracea Species 0.000 claims description 4
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 4
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 4
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 4
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 4
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 4
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 4
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 4
- 241001261506 Undaria pinnatifida Species 0.000 claims description 4
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 4
- 244000273928 Zingiber officinale Species 0.000 claims description 4
- 235000021329 brown rice Nutrition 0.000 claims description 4
- 239000008157 edible vegetable oil Substances 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 235000008397 ginger Nutrition 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 3
- 244000307697 Agrimonia eupatoria Species 0.000 claims description 3
- 244000144730 Amygdalus persica Species 0.000 claims description 3
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 3
- 244000105624 Arachis hypogaea Species 0.000 claims description 3
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 3
- 235000018262 Arachis monticola Nutrition 0.000 claims description 3
- 241000255789 Bombyx mori Species 0.000 claims description 3
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 claims description 3
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 claims description 3
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 claims description 3
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims description 3
- 240000008384 Capsicum annuum var. annuum Species 0.000 claims description 3
- 240000006162 Chenopodium quinoa Species 0.000 claims description 3
- 244000234623 Coprinus comatus Species 0.000 claims description 3
- 235000004439 Coprinus comatus Nutrition 0.000 claims description 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 3
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 3
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 3
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 3
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 3
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 3
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 3
- 240000000171 Crataegus monogyna Species 0.000 claims description 3
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 3
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 3
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 3
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 3
- 244000008991 Curcuma longa Species 0.000 claims description 3
- 241000208368 Euonymus alatus Species 0.000 claims description 3
- 102000007625 Hirudins Human genes 0.000 claims description 3
- 108010007267 Hirudins Proteins 0.000 claims description 3
- 241000237502 Ostreidae Species 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 3
- 235000014220 Rhus chinensis Nutrition 0.000 claims description 3
- 240000003152 Rhus chinensis Species 0.000 claims description 3
- 235000010208 anthocyanin Nutrition 0.000 claims description 3
- 239000004410 anthocyanin Substances 0.000 claims description 3
- 229930002877 anthocyanin Natural products 0.000 claims description 3
- 150000004636 anthocyanins Chemical class 0.000 claims description 3
- 235000013527 bean curd Nutrition 0.000 claims description 3
- 235000007215 black sesame Nutrition 0.000 claims description 3
- 229940104640 chinese yam extract Drugs 0.000 claims description 3
- 235000000125 common agrimony Nutrition 0.000 claims description 3
- 235000003373 curcuma longa Nutrition 0.000 claims description 3
- 235000004426 flaxseed Nutrition 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 235000020710 ginseng extract Nutrition 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims description 3
- 229940006607 hirudin Drugs 0.000 claims description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 3
- 235000020636 oyster Nutrition 0.000 claims description 3
- 235000020232 peanut Nutrition 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 235000013976 turmeric Nutrition 0.000 claims description 3
- 235000005282 vitamin D3 Nutrition 0.000 claims description 3
- 239000011647 vitamin D3 Substances 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- 229940021056 vitamin d3 Drugs 0.000 claims description 3
- 229940054810 white kidney bean extract Drugs 0.000 claims description 3
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 2
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 2
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 2
- 241000045403 Astragalus propinquus Species 0.000 claims description 2
- 241000167854 Bourreria succulenta Species 0.000 claims description 2
- 239000004278 EU approved seasoning Substances 0.000 claims description 2
- 241000222336 Ganoderma Species 0.000 claims description 2
- 240000000103 Potentilla erecta Species 0.000 claims description 2
- 235000016551 Potentilla erecta Nutrition 0.000 claims description 2
- 241000241413 Propolis Species 0.000 claims description 2
- 241001038563 Pseudostellaria Species 0.000 claims description 2
- 244000046146 Pueraria lobata Species 0.000 claims description 2
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 2
- 235000002226 Ranunculus ficaria Nutrition 0.000 claims description 2
- 244000081426 Ranunculus ficaria Species 0.000 claims description 2
- 241001165494 Rhodiola Species 0.000 claims description 2
- 241000612118 Samolus valerandi Species 0.000 claims description 2
- 241000121220 Tricholoma matsutake Species 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- 239000001138 artemisia absinthium Substances 0.000 claims description 2
- 235000006533 astragalus Nutrition 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- 235000019693 cherries Nutrition 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000010411 cooking Methods 0.000 claims description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 229940069949 propolis Drugs 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 240000001851 Artemisia dracunculus Species 0.000 claims 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 46
- 239000003472 antidiabetic agent Substances 0.000 abstract description 25
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract description 18
- 230000000087 stabilizing effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 244000302512 Momordica charantia Species 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 84
- 230000003750 conditioning effect Effects 0.000 description 61
- 206010012601 diabetes mellitus Diseases 0.000 description 57
- 102000004877 Insulin Human genes 0.000 description 42
- 108090001061 Insulin Proteins 0.000 description 42
- 229940125396 insulin Drugs 0.000 description 42
- 230000002829 reductive effect Effects 0.000 description 35
- 230000002354 daily effect Effects 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 32
- 239000008103 glucose Substances 0.000 description 32
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 31
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 238000000034 method Methods 0.000 description 26
- 230000037213 diet Effects 0.000 description 25
- 235000019197 fats Nutrition 0.000 description 21
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 19
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 206010022489 Insulin Resistance Diseases 0.000 description 16
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 16
- 235000015097 nutrients Nutrition 0.000 description 16
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 15
- 229930003316 Vitamin D Natural products 0.000 description 15
- 230000009471 action Effects 0.000 description 15
- 235000019166 vitamin D Nutrition 0.000 description 15
- 239000011710 vitamin D Substances 0.000 description 15
- 150000003710 vitamin D derivatives Chemical class 0.000 description 15
- 229940046008 vitamin d Drugs 0.000 description 15
- 244000285963 Kluyveromyces fragilis Species 0.000 description 14
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 14
- 150000001720 carbohydrates Chemical class 0.000 description 14
- 235000014633 carbohydrates Nutrition 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 108010010234 HDL Lipoproteins Proteins 0.000 description 13
- 102000015779 HDL Lipoproteins Human genes 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 13
- 229960003105 metformin Drugs 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 11
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 11
- 229930003779 Vitamin B12 Natural products 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 11
- 235000012054 meals Nutrition 0.000 description 11
- 229940116269 uric acid Drugs 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 235000019163 vitamin B12 Nutrition 0.000 description 11
- 239000011715 vitamin B12 Substances 0.000 description 11
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 10
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 10
- 229940107218 chromium Drugs 0.000 description 10
- 235000013372 meat Nutrition 0.000 description 10
- 230000002633 protecting effect Effects 0.000 description 10
- 208000024172 Cardiovascular disease Diseases 0.000 description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 9
- 235000013311 vegetables Nutrition 0.000 description 9
- 235000019158 vitamin B6 Nutrition 0.000 description 9
- 239000011726 vitamin B6 Substances 0.000 description 9
- 229940011671 vitamin b6 Drugs 0.000 description 9
- 208000019901 Anxiety disease Diseases 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000019658 bitter taste Nutrition 0.000 description 8
- 235000021152 breakfast Nutrition 0.000 description 8
- 210000001508 eye Anatomy 0.000 description 8
- 235000021384 green leafy vegetables Nutrition 0.000 description 8
- 235000014102 seafood Nutrition 0.000 description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 7
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 7
- 229930003270 Vitamin B Natural products 0.000 description 7
- 229930003471 Vitamin B2 Natural products 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000036506 anxiety Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 235000019152 folic acid Nutrition 0.000 description 7
- 239000011724 folic acid Substances 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 229960002477 riboflavin Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 235000019164 vitamin B2 Nutrition 0.000 description 7
- 239000011716 vitamin B2 Substances 0.000 description 7
- 241000251468 Actinopterygii Species 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 235000019688 fish Nutrition 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229960000304 folic acid Drugs 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- -1 liver Chemical compound 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 235000010374 vitamin B1 Nutrition 0.000 description 5
- 239000011691 vitamin B1 Substances 0.000 description 5
- 206010013789 Dry throat Diseases 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 241000408747 Lepomis gibbosus Species 0.000 description 4
- 208000008167 Magnesium Deficiency Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 235000019484 Rapeseed oil Nutrition 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 235000003434 Sesamum indicum Nutrition 0.000 description 4
- 244000040738 Sesamum orientale Species 0.000 description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000014171 carbonated beverage Nutrition 0.000 description 4
- 235000021158 dinner Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 235000004764 magnesium deficiency Nutrition 0.000 description 4
- 238000010339 medical test Methods 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- 238000011903 nutritional therapy Methods 0.000 description 4
- 235000014571 nuts Nutrition 0.000 description 4
- 235000020236 pumpkin seed Nutrition 0.000 description 4
- 235000011888 snacks Nutrition 0.000 description 4
- 235000019614 sour taste Nutrition 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 238000010025 steaming Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 208000010837 Diabetic eye disease Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 235000015468 Lycium chinense Nutrition 0.000 description 3
- 244000241872 Lycium chinense Species 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 229960004580 glibenclamide Drugs 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000003225 hyperhomocysteinemia Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960004329 metformin hydrochloride Drugs 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000020238 sunflower seed Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000009101 diabetic angiopathy Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 240000007440 Agaricus campestris Species 0.000 description 1
- 235000004570 Agaricus campestris Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 235000011274 Benincasa cerifera Nutrition 0.000 description 1
- 244000036905 Benincasa cerifera Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 206010066001 Cardiac autonomic neuropathy Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 235000016094 Magnolia denudata Nutrition 0.000 description 1
- 240000005819 Magnolia denudata Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000148137 Patrinia villosa Species 0.000 description 1
- 235000019109 Patrinia villosa Nutrition 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 206010073391 Platelet dysfunction Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 206010044278 Trace element deficiency Diseases 0.000 description 1
- 241000121219 Tricholoma Species 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008455 cerebrovascular function Effects 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000002824 diabetic encephalopathy Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000004530 effect on cardiovascular disease Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000004795 endocrine process Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000021059 hard food Nutrition 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021332 kidney beans Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000020903 low-carbon-diet Nutrition 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000009140 magnesium supplementation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- DEDOPGXGGQYYMW-UHFFFAOYSA-N molinate Chemical compound CCSC(=O)N1CCCCCC1 DEDOPGXGGQYYMW-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 231100000748 severe hepatic injury Toxicity 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a basic formula of a low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar and a functional food thereof, belonging to the field of nutritional foods, and comprising the following raw materials in parts by weight: 1-18 g of balsam pear extract, 1-12 g of laminarin, 1-12 g of astragalus extract, 1-12 g of medlar extract, 1-12 g of purified konjak powder, 1-18 g of pseudo-ginseng decoction piece raw powder, 1-18 g of American ginseng decoction piece raw powder, 1-18 g of poria cocos decoction piece raw powder, 1-18 g of fried cucumber seed raw powder, 1-12 g of fried semen cassiae decoction piece raw powder, 1-6 g of calcined mother-of-pearl decoction piece raw powder, 1-12 g of instant yeast powder and 2-18 g of polydextrose powder; the functional food can gradually reduce the dosage of hypoglycemic agent, and even can stop hypoglycemic agent to ensure that the blood sugar value is basically normal. The functional food has mild taste, convenient eating, safety, reliability, no toxic or side effect, good sugar stabilizing and controlling effects, and can be eaten for a long time.
Description
Technical Field
The invention discloses the technical field of human nutrition and health care, in particular to a basic formula of a low-carbon nutrition functional food for comprehensively regulating and controlling blood sugar and a functional food thereof.
Background
Diabetes is one of the common conditions of humans, and the pathogenesis of diabetes is: the utilization, ingestion and combination of sugar by the liver and muscle are faulty, which on the one hand represents hyperglycemia in blood and on the other hand, the sugar energy supply of tissues and organs is insufficient. Muscle sugar is insufficient in energy supply, so that symptoms such as emaciation and hypodynamia occur, and in order to solve the energy deficiency, people feel hunger and self-feedback want to solve the sugar energy deficiency. The pathogenesis of diabetes is that cells and tissues lack sugar, and human feedback is that the people do not eat too little, and the problem that the cells and tissues lack sugar is solved by overfeeding, so overfeeding and hunger occur.
At present, the patients with the polysaccharide urine just begin to take various chemical western medicines, and the blood sugar is rapidly reduced. However, this blood glucose drop is temporary, at the cost of blocking nutrient absorption by the human body, and the drug causes significant injury and side effects to the body. For example: the side effects of gastrointestinal reactions such as anorexia, nausea, abdominal distention, diarrhea, intestinal discomfort, dry mouth or metallic taste are common in the administration of metformin, and complications such as liver, stomach, heart, brain, eyes and the like can easily occur after long-term administration, for example, lactic acidosis can be caused by taking a large amount of biguanide drugs; acarbose (bailing) and voglibose (ploidy) are taken, and have side effects of digestive tract reactions such as borborygmus, abdominal distention, nausea, vomiting, anorexia, occasional diarrhea and the like, and can easily cause intestinal diseases and influence liver and kidney functions after long-term administration; the liver is damaged by taking troglitazone, and the pioglitazone and the rosiglitazone are easy to cause side effects such as edema, blood dilution, red blood cells, hemoglobin reduction and the like, and fatal severe liver injury occurs in a few cases. Currently, western medicine methods for treating diabetes are commonly used only with drugs such as insulin and hypoglycemic agents. The effect of the medicine can only maintain the blood sugar level at a certain stage, and cannot solve the occurrence and development of diabetes complications.
Therefore, whether to develop a food product capable of comprehensively regulating and controlling blood sugar so as to overcome the defects of the Western medicine is a problem to be solved urgently.
Disclosure of Invention
In view of the above, the invention provides a basic formula of a low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar and a functional food thereof, so as to solve the problems of short-term effect of chemical drugs in Western medicine in treating diabetes and unstable blood sugar.
In one aspect, the invention provides a basic formula of a low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar, which comprises the following raw materials in parts by weight: 1-18 g of balsam pear extract, 1-12 g of laminarin, 1-12 g of astragalus extract, 1-12 g of medlar extract, 1-12 g of purified konjak powder, 1-18 g of pseudo-ginseng decoction piece raw powder, 1-18 g of American ginseng decoction piece raw powder, 1-18 g of poria cocos decoction piece raw powder, 1-18 g of fried cucumber seed raw powder, 1-12 g of fried semen cassiae decoction piece raw powder, 1-6 g of calcined mother-of-pearl decoction piece raw powder, 1-12 g of instant yeast powder and 2-18 g of polydextrose powder.
Preferably, the base formulation comprises the following raw materials by weight: 3 g of balsam pear extract, 2 g of laminarin, 2 g of astragalus extract, 2 g of medlar extract, 3 g of purified konjaku flour, 3 g of pseudo-ginseng decoction piece raw powder, 3 g of American ginseng decoction piece raw powder, 3 g of poria cocos decoction piece raw powder, 3 g of stir-fried cucumber seed raw powder, 2 g of stir-fried semen cassiae decoction piece raw powder, 1 g of calcined mother-of-pearl decoction piece raw powder, 2 g of instant yeast powder and 3 g of polydextrose powder.
Further preferably, the base formulation further comprises the following raw materials by weight: 3-15 g of edible vegetable oil and/or 0.5 g of refined salt;
wherein the edible vegetable oil is olive oil, linseed oil or chia seed oil.
On the other hand, the invention also provides a low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar, which comprises any one of the basic formula, a nutritional supplement, a dietary therapy composition, a coarse cereal composition, a health care product and one or more of traditional Chinese medicine decoction pieces;
the nutritional supplement is one or more of astaxanthin or anthocyanin soft capsules 1 granule, B vitamin tablet 1 tablet, lipoic acid soft capsule 1 granule, chromium yeast soft capsule 1 granule, vitamin A soft capsule or multidimensional element 1 granule, vitamin E soft capsule 1 granule, vitamin C tablet 1 tablet, magnesium element tablet 1 tablet, zinc element tablet 1 tablet, vitamin D3 tablet 1 tablet and deep sea fish oil soft capsule 1 granule;
the dietetic composition consists of 250 milliliters of pure milk or warm water, 4-6 pieces of black fungus, 20-30g of walnut, 1 egg, 3g of dried small shrimps and 2g of refined salt; or comprises Chinese cabbage 80g, herba Zosterae Marinae 50g, bean curd 60g, rhizoma Zingiberis recens 3 pieces, flavoring and refined salt; or comprises undaria pinnatifida 60g, cabbage 100g, streaky pork 50g, flavoring and refined salt; or consists of 50g of tricholoma matsutake, 100g of green pepper, seasonings and refined salt; or 60g of coprinus comatus, 100g of chicken, seasoning and refined salt; or consists of kidney bean 100g and pork 80 g;
The coarse cereal composition comprises 50g of whole tartary buckwheat, 20g of sorghum rice, 10g of soybean or white kidney bean, 10g of peanut, 3g of black sesame and 3g of flaxseed or chia seed; or 50g of tartary buckwheat, 10g of gorgon fruit, 10g of lotus seed, 10g of oat, 10g of brown rice and 10g of quinoa; or comprises Coicis semen 100g, semen Phaseoli 30g, fructus Benincasae 100g and radix Polygoni Multiflori rhizoma Dioscoreae 50 g;
the health care product is one or more of black fungus extract 5g, ginseng extract 3g, chinese yam extract 5g, oyster peptide extract 5g, hawthorn polysaccharide 5g, hirudin 3g, ganoderan 5g, white kidney bean extract 5g, tagatose 5g, arabinose 5g, propolis 5g or blood sugar balance tablet 1;
the traditional Chinese medicine decoction pieces are one or more of 20g of hairyvein agrimony, 30g of herba patriniae, 20g of discolor cinquefoil herb, 10g of Chinese gall, 5g of white muscardine silkworm, 10g of Chinese yam, 10g of gorgon fruit, 10g of lotus seed, 5g of dried ginger, 5g of bunge cherry seed, 5g of peach seed, 10g of medlar, 5g of turmeric, 10g of rhodiola root-tuber powder, 10g of kudzuvine root powder, 5g of ginseng, 5g of pseudostellaria root, 5g of rhizoma atractylodis, 10g of winged euonymus twig, 10g of diverse wormwood herb, 10g of figwort root, 10g of cortex lycii radicis, 10g of astragalus mongholicus, 10g of lucid ganoderma, 3g of scented tea and 3g of green tea.
Preferably, when the food product consists of a base formula and a nutritional supplement, the base formula is 95-99 grams by weight and the nutritional supplement is 1-5 grams;
When the food consists of a basic formula and a dietary therapy composition, the basic formula is 20-30 g by weight, and the dietary therapy composition is 30-70 g by weight;
when the food consists of a basic formula and a coarse cereal composition, the basic formula is 30-50 g, and the coarse cereal composition is 50-70 g;
when the food consists of a basic formula and a health-care product, the basic formula is 30-50 g and the health-care product is 50-70 g by weight;
when the food consists of a basic formula and Chinese medicinal decoction pieces, the basic formula is 50-70 g by weight, and the Chinese medicinal decoction pieces are 30-50 g by weight.
Further preferably, the specific preparation method of the coarse cereal composition comprises the following steps: cleaning food materials, soaking coarse cereals in warm water, adding yeast powder, adding 100 ml warm water, sealing, placing in 25-30deg.C heat preservation environment, taking out after micro fermentation, and cooking in pressure cooker or common electric rice cooker to obtain dry rice or porridge.
Further preferably, the food is in the form of a powder, granule, dry tablet, beverage or canned porridge for convenient consumption.
The low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar provided by the invention takes the composite food material compound as a basic formula, combines various specified food sugar control in daily diet, can also combine commercial nutrients, and has the purpose of dialectically supplementing nutrition imbalance and malnutrition caused by diabetes; can also be combined with special traditional Chinese medicine decoction pieces and traditional Chinese medicine extracts to treat II diabetes mellitus, and is simply summarized as follows: dialectical diet + dialectical nutrient supplement + dialectical traditional Chinese medicine treatment (comprising traditional Chinese medicine decoction pieces and traditional Chinese medicine extract).
The low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar provided by the invention has the main innovation points that:
1) For foods with good sugar control effect and large dosage which can not be used as both medicine and food of the formula, the essence components such as balsam pear extract, laminarin and the like are used, so that the defects of bitter taste of traditional Chinese medicine and poor compliance of patients taking the medicine for a long time are overcome;
2) For the traditional Chinese medicine decoction pieces with good sugar control effect and small drug property deviation and homology of medicine and food, such as pseudo-ginseng powder, american ginseng powder and the like, the disadvantage of expensive price of the medicine extract is avoided, and common people can take the medicine for a long time;
3) The nutritional food has high nutritional value, is suitable for diabetics to control sugar, is used as far as possible in a formula, such as nutritional yeast powder, and reflects the thinking method that nutritional intake medicine is not as good as food and food is essential;
4) For improving intestinal beneficial flora, the direct access formula of dietary fiber food for improving satiety and controlling blood sugar, such as purified konjaku flour, polydextrose powder and the like, can indirectly provide nutrients for human bodies, provide high-quality food-prebiotics for probiotics, keep the ecological balance of the intestinal flora, exert the function of producing nutrition of the intestinal beneficial flora and indirectly provide nutrients for the human bodies.
The low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar has the characteristics of combining traditional Chinese medicine with low-carbon diet and nutrients, and has the overall effects of regulating yin and yang in traditional Chinese medicine, regulating and controlling blood sugar in diet and repairing damaged cell tissues in nutrition.
The low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar provided by the invention has the advantages that most of selected food materials have the function of controlling the blood sugar, and as diabetes has complex illness and more complications, the simple use of 1 or more food materials is obviously worry, and the curative effect is not ideal; thus, formulation compounding is particularly important.
Nutrient formula and secondary formula efficacy and action description
Nutrients are nutrients which are required to be taken from the outside because the human body cannot synthesize the nutrients while maintaining normal growth, development and metabolism of the human body. After these substances enter the human body, one part can convert or synthesize the nutrients required by the human body, while the other part cannot be synthesized in the human body and needs to be supplied in vitro, which is called as the necessary nutrients for the human body. The key nutrients relevant to the present invention are described in detail below.
1. Astaxanthin efficacy and action description:
regulating blood lipid: low high density lipoprotein has been considered as a cardiovascular risk factor, and is susceptible to cardiovascular disease when the human high density lipoprotein is below 1.2 mmol/L; astaxanthin is 12-16 mg/day, which is beneficial to improving HDL high density lipoprotein and adiponectin, and effectively solves the problem of low high density lipoprotein.
Conditioning diabetes and complications: astaxanthin is the most powerful antioxidant found in nature by humans today. The antioxidant capacity of astaxanthin is 6000 times that of vitamin C, 800 times that of coenzyme Q10, 550 times that of green tea catechol, 500 times that of vitamin E, 75 times that of alpha-lipoic acid and 11 times that of beta-carotene. Acting on diabetic cardiovascular disease. Astaxanthin protects the vascular endothelial layer, promotes blood flow, and protects the low density lipoprotein cholesterol from oxidation (damage). Acting on diabetic encephalopathy. One particular property of astaxanthin is its ability to cross the blood brain barrier and the retinal barrier, thereby protecting the brain and eyes, protecting brain cells from inflammatory reactions, and protecting the brain and eyes from alzheimer's disease, macular degeneration and other degenerative diseases. Acts on diabetic eye diseases. Preventing eye fatigue, improving vision and depth perception, and increasing blood flow of eye tissue. Acting on glycometabolism diseases, insulin resistance and metabolic syndrome. Is helpful for optimizing the antioxidant state and preventing vascular injury. Protect immune cells from injury and enhance certain immune functions.
Description of b vitamins efficacy and action:
conditioning diabetes: the main characteristic of II diabetes is insulin resistance, and a large amount of B vitamins are consumed in the insulin resistance process. B vitamins are an important class of vitamins that are easily lost in the body of diabetics because all B vitamins are involved in chemical reactions within the body's cells and gain energy and nutrition from fat, protein and carbohydrates. And refined foods, such as refined rice and flour, which we eat at ordinary times, cause a great loss of vitamin B, so that diabetics cannot obtain sufficient vitamin B to cause malnutrition. Can help diabetics to prevent malnutrition by taking B vitamins. For example, in diabetics, urine contains a large amount of uric acid due to insufficient intake of vitamin B6, indicating that the pancreas has been destroyed. If 50ppm vitamin B6 is administered, the uric acid content in urine will be reduced very rapidly. The vitamin B group has important effects on improving blood sugar and reducing diabetic complications. At present, the effects of reducing blood sugar and preventing and treating complications, which are proved by students, comprise vitamins B1, B2, B6, B12, nicotinic acid, pantothenic acid, folic acid and the like. Relieving side effects of the medicine. Prolonged administration of metformin causes vitamin B12 deficiency and is prone to diabetic peripheral neuritis. Thus, a long-term administration of metformin is required for the sugar-friendly supplement of vitamin B12, especially in elderly diabetics.
Protecting cardiovascular and cerebrovascular functions: vitamin B2 can protect blood vessel, prevent arteriosclerosis, and has good effect on preventing cardiovascular diseases of sugar friends. The recommended daily vitamin B2 intake for adults is 1.4mg. The content of vitamin B2 in Agaricus campestris, herba Zosterae Marinae, and thallus Porphyrae is high.
Prevention of diabetic neuropathy: vitamin B12 can reduce and relieve diabetic neuropathy such as peripheral neuritis, and has the same meaning for preventing diabetic neuropathy. The recommended daily intake of vitamin B12 for adults is 2.4mg. For the sugar friends who frequently eat the metformin, vitamin B12 is easily deficient, people usually need to pay attention to the supplement of foods rich in vitamin B12 such as liver, fish, milk and the like so as not to cause nutritional deficiency diseases such as anemia and the like.
Prevention of retinopathy: vitamin B6 is an indispensable role in preparing epinephrine and insulin, and researches show that vitamin B6 is helpful for preventing retinopathy caused by diabetes, scavenging free radicals in vivo, protecting liver, improving eyesight, and relieving symptoms of neurological diseases.
Reducing homocysteine effects: in recent years, research at home and abroad shows that hyperhomocysteinemia is closely related to II diabetes. Homocysteine (HCY) is a metabolite of methionine, a sulfur-containing amino acid that does not participate in protein synthesis. Homocysteine is high in the body, and a series of endocrine processes of the human body can be stimulated, so that insulin resistance is induced. Insulin resistance is the leading cause of diabetes mellitus. II diabetes patients can lower insulin resistance by lowering homocysteine, thereby controlling blood sugar. Serum homocysteine in humans is inversely related to serum folate and vitamin B12 levels, so that ii diabetics help control blood glucose by supplementing folate, vitamin B6 and B12.
3. Lipoic acid efficacy and action description:
blocking diabetic glycosylation. Lipoic acid is mainly used for preventing sugar from combining with protein, namely has the function of anti-saccharification, so that the blood sugar value can be easily stabilized, the sensitivity of diabetes cells to insulin is obviously improved, the generation of ATP in the cell energy circulation is increased, and the myocardial lesions complicated with diabetes are improved. Lipoic acid can block glycosylation, prevent accumulation of glycosylation products, and help prevent chronic complications of diabetes. And has adjuvant therapeutic effect on arteriosclerosis, cataract, fatty liver and other complications of diabetes.
Protecting heart action: lipoic acid is useful in the treatment of diabetic cardiovascular disease. Lipoic acid is an essential factor in the energy metabolism and circulation of human glucose, and sulfur-containing amino acids in diet are all element sources for lipoic acid synthesis, although human body can synthesize lipoic acid required by basic physiological reaction by itself. However, because of metabolic disorder of diabetics and relative insufficient synthesis of lipoic acid, the lipoic acid preparation is additionally supplemented, so that the sensitivity of the cells of the diabetics to insulin can be obviously improved, the generation of Adenosine Triphosphate (ATP) in the energy circulation of the cells can be increased, and the method has important significance for improving the diabetic myocardial lesions. Supplementing lipoic acid in diabetics may reduce the risk of affecting cardiac neurological complications, as about 25% of diabetics may develop Cardiovascular Autonomic Neuropathy (CAN). CAN is characterized by reduced or accelerated heart rate variability and is associated with increased risk of mortality in diabetics.
Brain protecting effect: lipoic acid in the blood stream can cause increased amounts of glutathione in the brain. The lipoic acid molecule is very small enough to silently flow through the blood brain barrier, and once inside the brain it mysteriously regenerates glutathione, other antioxidants have no such function.
Conditioning diabetic nephropathy: the lipoic acid has antioxidant stress effect related to the special disulfide bond antioxidant molecular structure, has water solubility and fat solubility, can penetrate into various parts in cells, eliminates various free radicals, and has powerful antioxidant effect. Lipoic acid is the only etiological therapeutic drug for treating diabetic peripheral neuropathy at present, and the treatment report of lipoic acid for diabetic nephropathy is gradually increasing. Several researches show that the lipoic acid can effectively reduce the discharge of urine albumin, protect kidney function, remove various free radicals in the body, protect vascular endothelial function, chelate high-valence cations and stabilize the charge barrier of the filter membrane, thereby effectively reducing the discharge of urine albumin. Lipoic acid corrects oxidative stress caused by hyperglycemia through a variety of mechanisms, such as inhibiting lipid peroxidation, regulating nitric oxide-mediated endothelium-dependent vasodilation,
Conditioning diabetic eye disease: long-term use of lipoic acid has a good effect on the development and progression of retinopathy, as it can prevent oxidative damage that can lead to retinal DNA modification. With the age, the vision of people becomes weaker, so people need to regulate diet before the elderly, eat more balanced and rich foods, and prevent early eye tissue degradation or vision loss.
Modulating central and peripheral nervous actions: (1) acting on the central nerve: lipoic acid can inhibit senile dyszhia: senile dyszhia is a problem of cerebral vascular oxidization and inflammation, and lipoic acid has strong antioxidation effect, can resist aging, activate cells and improve physique. Lipoic acid supplements further help patients prevent suffering from neuronal damage, hypomnesis, dyskinesia, and altered cognitive function due to their antioxidant activity. ALA can easily enter the brain through the blood brain barrier, protecting delicate brain and nervous tissue, and it can also be used to prevent stroke and other brain problems. Experiments on rats show that ALA can help reverse the damage of brain aging cells, improve memory, reduce oxidative damage and improve mitochondrial function, and plays a certain role in preventing aging. (2) Has obvious effect of treating peripheral neuropathy. Lipoic acid can effectively inhibit diabetic peripheral neuropathy, regulate and balance oxidative stress of patients, increase insulin sensitivity, and promote transportation and utilization of glucose. The antioxidation effect of the lipoic acid has important significance for preventing and treating the occurrence and development of diabetic vascular complications.
4. Description of chromium element efficacy and action:
stabilizing blood glucose: the diabetes patients can cause electrolyte metabolism disorder in the body due to the disorder of sugar metabolism, so that discharged chromium is increased, and the diabetes patients also have the problems of reduced capability of converting the chromium into active chromium and poor utilization rate of the chromium, so that the dietary chromium can not meet the requirements of the diabetes patients and needs to be additionally supplemented.
Reducing glycosylated hemoglobin effect: improving abnormal glucose tolerance, reducing dosage of hypoglycemic drugs, and reducing blood lipid.
Improving glucose tolerance deficiency effect: chromium, niacin and glutathione together form a Glucose Tolerance Factor (GTF), which is a cofactor of insulin, can increase the efficacy of insulin, promote the body to utilize glucose, and can also influence the transport of amino acids in the body.
Effect of chromium on vision: the chromium is supplemented to improve vision and cataract. The chromium element is timely supplemented, so that the ametropia caused by diabetes can be improved, and cataract is prevented.
5. Description of mineral efficacy and action:
mineral substances have various functions: tissue formation, enzyme formation, hormone formation, and enzyme activation. Study results: diabetes is found to be closely related to trace element deficiency of human body. The microelements can assist in synthesizing insulin and participate in the absorption of blood sugar by cells. If the trace elements are insufficient, the absorption effect of the cells on blood sugar is poor, and hyperglycemia is necessarily caused.
6. Description of vitamin E efficacy and action:
conditioning cardiovascular disease effects: vitamin E supplements significantly reduce the chance of heart disease and associated death in diabetics carrying a particular gene. After 18 months of daily administration of 400 International units of vitamin E, diabetics carrying the haptoglobin (Hp) 2-2 gene had a 50% lower probability of heart attacks than placebo-administered Hp2-2 patients. 40% of diabetics carry the Hp2-2 gene. The greatest difference is the reduced number of heart attacks in patients taking vitamin E.
Prevention of vascular rupture action: vitamin E helps to protect the vessel wall, since the vessel wall is also made up of membranes, which prevents the dead cells from constantly shedding. And simultaneously, the vitamin E can stimulate the regeneration of blood vessels, repair scar tissues and has the function of anticoagulation so as to improve the symptoms of stroke.
Preventing small microvascular lesions: vitamin E can reduce erythrocyte lipid peroxidation in non-insulin dependent diabetics, which is important for the treatment of early stage diabetic vascular disease. The diabetic patient has platelet and endothelial dysfunction. Vitamin E can improve platelet and endothelial function. Large doses of vitamin E can reduce PKC activity, thereby improving glomerular and retinal function in diabetic mice. Vitamin E can improve vascular endothelial cell and microvascular function damage caused by hyperglycemia, and relieve diabetic retinopathy, diabetic nephropathy, and diabetic nervous system disorder.
7. Description of vitamin C efficacy and action:
the administration of large doses of vitamin C can reduce blood sugar and improve sugar metabolism and lipid metabolism, so that vitamin C should be properly added in the combined treatment of diabetes.
Regulating blood sugar and blood lipid: diabetics need to ingest more vitamin C to achieve the effect of improving blood glucose. This is because glucose has a similar structure to vitamin C and has a certain competitive relationship in terms of absorption and utilization, and therefore, the absorption and utilization ratio of vitamin C in a person having a high blood glucose level is lower than that in a normal person, and accordingly, higher intake is required.
Preventing diabetes mellitus effect: it was found that people with vitamin C intake exceeding 117mg/d (adults in our country recommended vitamin C intake of 100 mg/d) had a lower Relative Risk (RR) for developing diabetes, with vitamin C intake of less than 46% of those with 69mg/d (Zhou, 2016). Higher vitamin C intake has the effect of reducing the relative risk of diabetes.
8. Description of magnesium element efficacy and action:
magnesium is a cell activator. Magnesium is the second messenger of insulin, and magnesium deficiency can block the exertion of various effects of insulin and interfere with the normal progress of cellular metabolism. The magnesium element can repair or protect the biological functions of islet B cells, and improve the quality and the receptor number of insulin; simultaneously reduces insulin resistance, and further plays roles in regulating blood sugar and blood fat and maintaining normal level thereof. In addition, magnesium element can reduce or improve hardening of large and small blood vessels, increase elasticity of coronary blood vessels and permeability of capillaries, promote blood circulation, and has positive preventive effect on diabetic coronary heart disease, etc. Magnesium deficiency in human body can produce insulin resistance, reduce carbohydrate tolerance, accelerate atherosclerosis, and affect blood lipid and blood pressure. Magnesium supplementation in diabetics is an effective measure in preventing retinopathy. Magnesium is also a component of various enzymes in the body and plays an important role in normal metabolism of the body and in cell electron transfer. In the metabolism of sugar, magnesium can promote the passage of sugar through cell membrane, promote oxidative phosphorylation and glycolysis of sugar; meanwhile, magnesium is used as coenzyme to strengthen the operation of sugar on cell membranes, so that the cell can utilize the sugar. Magnesium is involved in regulating thermal energy metabolism and various enzymatic reactions. Magnesium deficiency and hypomagnesemia of the body will have an adverse effect on many metabolic processes. The lack of magnesium can lead to reduced insulin sensitivity, and the increase of magnesium intake in diet has important effect on preventing type II diabetes, and also has important effect on chronic complications such as diabetes complicated with hypertension and atherosclerosis. Thus, magnesium deficiency will result in reduced sensitivity of islet beta cells to sugar, resulting in inadequate insulin synthesis and secretion leading to disturbed sugar metabolism.
9. Description of efficacy and action of zinc element:
both type I and type II diabetes mellitus patients are generally lack of zinc, and complications of diabetes mellitus are related to reduction of intracellular zinc and zinc-dependent antioxidant enzymes (note: the normal play of the antioxidant function of the enzymes depends on zinc); the zinc supplement for diabetics can obviously reduce blood sugar and blood cholesterol level, so that the zinc-containing food additive can be used as a preventive measure for type 2 diabetes.
Prescription to aid zinc absorption: selenium + vitamin a + vitamin C + vitamin E.
10. Description of vitamin D efficacy and action:
reducing insulin resistance effects: vitamin D can regulate the production of inflammatory cytokines, thereby improving insulin resistance. Vitamin D also inhibits inflammatory responses in the body and regulates immune function in the body. If vitamin D is deficient, it is possible to increase the risk of insulin resistance, which is the most critical risk factor for the development of diabetes.
Increasing insulin sensitivity effects: vitamin D reduces the risk of developing type I diabetes and also improves glycemic control, insulin sensitivity, or insulin resistance in type I and type II diabetics. Vitamin D or its analogues can increase insulin secretion in type 2 diabetes patients, and prevent bone loss in primary type 2 diabetes patients.
Promoting insulin secretion: vitamin D can promote insulin synthesis and secretion, relatively increase insulin sensitivity, and vitamin D is beneficial to increasing the absorption of calcium by human body and maintaining reasonable level of calcium in blood, thereby being beneficial to normal transmission of calcium signals required by insulin secretion.
Inhibition of islet apoptosis: vitamin D indirectly protects islet cells: the 1,25- (OH) 2D3 can inhibit secretion of Th1 and cytokines in vivo and in vitro by regulating dendritic cells, or convert Th1 into Th2, inhibit cellular immunity, so as to reduce damage of cytotoxic T lymphocytes to islet cells, thereby slowing down apoptosis of islet cells, protecting islet cells and maintaining functions thereof.
Alleviating diabetic retinopathy: vitamin D can play a kidney protecting role by inhibiting renin synthesis and down-regulating the RAS system.
Reducing the incidence of cardiovascular disease: the learner finds that the incidence rate of cardiovascular diseases of type II diabetes patients with slight renal insufficiency is inversely related to the plasma vitamin D level, and low vitamin D is an independent risk factor for the incidence of cardiovascular diseases of people, so that the incidence rate of cardiovascular diseases of diabetes patients can be improved by supplementing vitamin D.
Modulating autonomic dysfunction: vitamin D supplementation may improve cardiac autonomic neuropathy in diabetics to some extent.
Vitamin D sugar control mechanism: if the calcium in the human body is insufficient, the transmission signal is weak, insulin secretion by islet beta cells can be insufficient, and blood sugar can be high; if the calcium in the body is sufficient, the signal transmission is strong, the insulin secretion of the islet beta cells can be sufficient, and the blood sugar can be controlled at a reasonable level. This is the mechanism by which calcium helps to improve insulin secretion and thus control hyperglycemia.
11. Description of deep sea fish oil efficacy and action:
antihypertensive effect: although the effect is not particularly pronounced, its overall effect on cardiovascular disease is reliable. Numerous studies have shown that omega-3 fatty acids can reduce the risk of mortality from heart disease, stroke. Omega-3 fatty acids are also considered by many doctors as important adjunctive therapeutic nutrients for diabetes and metabolic syndrome.
The invention provides a basic formula and a processing method of low-carbon nutritional functional food, which comprises the following specific steps:
1. grinding the selected raw materials of the Chinese medicinal decoction pieces for both medicine and food into 100 meshes of fine powder;
2. mixing polysaccharide powder compound according to the formula proportion;
3. The health care product is taken according to the indicated dosage or according to the instruction of the commercial product;
4. the nutritional supplement selects 1 or more corresponding nutrients according to different symptoms, and is taken together with the formula product;
5. the selected coarse cereals, vegetables, fish meat, milk and the like can be taken together with the formula product, and can be taken as daily diet according to the daily meal time, so that the low-carbohydrate food is taken in a proper amount, and the high-carbohydrate food is forbidden.
The eating method comprises the following steps:
1. the dosage of the low-carbon nutritional functional food is as follows: the composition can be taken by adults 1 day and 1-2 times, 30g each time, in the morning and evening.
2. Mixing with warm water to obtain paste, and optionally adding sugar-free pure milk.
The method is suitable for people: people with high sugar content, people with pre-diabetes and early diabetes, obesity, constipation and low resistance. Can also be used for sub-health people and people suffering from chronic non-infectious diseases.
The low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar, provided by the invention, integrates the medical and edible functions of traditional Chinese medicine and the supplement of plant nutrients, takes nutritional diet as a main body, can be eaten for a long time, is free of toxic and side effects, is safe and reliable, can effectively control blood sugar, and is suitable for being used with other methods for controlling blood sugar (medicines or foods and the like); other methods are not excluded, but the curative effect of other methods for treating diabetes can be enhanced.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as disclosed.
Detailed Description
The invention is further illustrated by the following examples.
Example 1
A low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar is prepared from 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjak powder, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of fried cucumber seed raw powder, 2g of fried semen cassiae decoction piece raw powder, 1g of calcined mother-of-pearl decoction piece raw powder, 2g of imported instant nutritional yeast powder and 3g of polydextrose powder (the above formula is the basic formula). Or adding 5g of olive oil (general purpose), or using 5g of linseed oil (female), or 5g of Qiya seed oil (female), etc. for metering.
Example 2
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from 1g of balsam pear extract, 1g of laminarin, 1g of astragalus extract, 1g of medlar extract, 1g of purified konjak powder, 1g of pseudo-ginseng decoction piece raw powder, 1g of American ginseng decoction piece raw powder, 1g of poria cocos decoction piece raw powder, 1g of stir-fried cucumber seed raw powder, 1g of stir-fried semen cassiae decoction piece raw powder, 1g of calcined mother-of-pearl decoction piece raw powder, 2g of imported instant nutritional yeast powder, 2g of polydextrose powder, 3g of olive oil (general purpose), 5g of linseed oil, 5g of chia seed oil (female) or the like.
Example 3
A low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar is prepared from 18g of balsam pear extract, 12g of laminarin, 12g of astragalus extract, 12g of medlar extract, 12g of purified konjak powder, 18g of pseudo-ginseng decoction piece raw powder, 18g of American ginseng decoction piece raw powder, 18g of poria cocos decoction piece raw powder, 18g of fried cucumber seed raw powder, 12g of fried semen cassiae decoction piece raw powder, 6g of calcined mother-of-pearl decoction piece raw powder, 12g of imported instant nutritional yeast powder and 18g of polydextrose powder. Or 3g of olive oil (general purpose), or 5g of linseed oil, or 5g of chia seed oil (female) can be used according to the dosage.
Example 4
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjak powder, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of fried cucumber seed raw powder, 2g of fried semen cassiae decoction piece raw powder, 1g of calcined mother-of-pearl decoction piece raw powder, 2g of imported instant nutritional yeast powder, 3g of polyglucose powder (total 32g of basic formula), 1 granule of astaxanthin (or anthocyanin) soft capsule, 1 granule of B-group vitamin tablet, 1 granule of lipoic acid soft capsule, 1 granule of chromium yeast soft capsule, 1 granule of vitamin A soft capsule (or silver-rich multi-vitamin tablet), 1 granule of vitamin E soft capsule, 1 granule of vitamin C tablet, 1 tablet of magnesium element tablet, 1 tablet of zinc element tablet, 1 tablet of vitamin D3 tablet, 1 granule of deep sea fish oil soft capsule (compound) and the like.
Example 5
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjak powder, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of stir-fried cucumber seed raw powder, 2g of stir-fried semen cassiae decoction piece raw powder, 1g of calcined nacre decoction piece raw powder, 2g of imported instant nutritional yeast powder, 3g of polydextrose powder (32 g in total of basic formula), 1 bag of pure milk (250 ml), 4-6 sheets (about) of black fungus, 2 (20-30 g) of walnut, 1 egg, 3g of dried small shrimp, 2g of refined salt (indicating that male does not need milk, 200 ml of warm water) and the like.
Example 6
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjak powder, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of fried cucumber seed raw powder, 2g of fried semen cassiae decoction piece raw powder, 1g of calcined mother-of-pearl decoction piece raw powder, 2g of imported instant nutritional yeast powder, 3g of polydextrose powder (32 g in total of basic formula), 80g of Chinese cabbage, 50g of kelp, 60g of bean curd, 3 pieces of ginger, and a little flavoring and refined salt; secondary formula 3: the undaria pinnatifida 60g, cabbage 100g, streaky pork 50g, and a little refined salt can be used according to the dosage.
Example 7
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjak powder, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of fried cucumber seed raw powder, 2g of fried semen cassiae decoction piece raw powder, 1g of calcined mother-of-pearl decoction piece raw powder, 2g of imported instant nutritional yeast powder, 3g of polydextrose powder (32 g in total of basic formula), 60g of undaria pinnatifida, 100g of cabbage, 50g of pork with five flowers, a small amount of refined salt and the like.
Example 8
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjak powder, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of fried cucumber seed raw powder, 2g of fried semen cassiae decoction piece raw powder, 1g of calcined nacre decoction piece raw powder, 2g of imported instant nutritional yeast powder, 3g of polydextrose powder (32 g in total of basic formula), 50g of tricholoma, 100g of green pepper, a little flavoring and refined salt; secondary formula 6: kidney beans 100g, pork 80g, etc. can be used in a metered amount.
Example 9
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjak powder, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of stir-fried cucumber seed raw powder, 2g of stir-fried semen cassiae decoction piece raw powder, 1g of calcined mother-of-pearl decoction piece raw powder, 2g of imported instant nutritional yeast powder, 3g of polydextrose powder (total 32g of basic formula), 50g of tartary buckwheat, 20g of sorghum rice, 10g of black sesame, 20g of white kidney bean for male, 20g of soybean (or soybean product) for female, 10g of flax seed (or chia seed) for female, 20g of Chinese yam, 20g of gorgon seed, 20g of lotus seed, 20g of oat, 20g of coix seed, 30g of brown rice and the like.
Example 10
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from the following components of 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjaku flour, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of fried cucumber seed raw powder, 2g of fried semen cassiae decoction piece raw powder, 1g of calcined mother-of-pearl decoction piece raw powder, 2g of imported instant nutritional yeast powder, 3g of polydextrose powder (32 g in total of basic formula) and 2g of cereal diet therapy secondary formula: 50g of tartary buckwheat, 10g of gorgon fruit, 10g of lotus seed, 10g of oat, 10g of brown rice and 10g of quinoa can be used according to the metering.
Example 11
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjak powder, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of fried cucumber seed raw powder, 2g of fried semen cassiae decoction piece raw powder, 1g of calcined mother-of-pearl decoction piece raw powder, 2g of imported instant nutritional yeast powder, 3g of polydextrose powder (total 32g of basic formula), 100g of coix seed, 30g of red bean, 100g of white gourd and 50g of iron yam; formula 5: 60g of coprinus comatus, 100g of chicken and less seasoning and refined salt are allowed to be used according to the metering.
Example 12
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjak powder, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of fried cucumber seed raw powder, 2g of fried semen cassiae decoction piece raw powder, 1g of calcined mother-of-pearl decoction piece raw powder, 2g of imported instant nutritional yeast powder, 3g of polydextrose powder (total 32g of basic formula), 3g of ginseng extract, 3g of American ginseng extract, 3g of Chinese yam extract, 3g of oyster peptide extract, 3g of hawthorn polysaccharide, 3g of hirudin, 5g of ganoderma lucidum polysaccharide, 3g of white kidney bean extract and the like.
Example 13
A low-carbon nutritional functional food for comprehensively regulating blood sugar is prepared from 3g of balsam pear extract, 2g of laminarin, 2g of astragalus extract, 2g of medlar extract, 3g of purified konjak powder, 3g of pseudo-ginseng decoction piece raw powder, 3g of American ginseng decoction piece raw powder, 3g of poria cocos decoction piece raw powder, 3g of fried cucumber seed raw powder, 2g of fried semen cassiae decoction piece raw powder, 1g of calcined nacre decoction piece raw powder, 2g of imported instant nutritional yeast powder, 3g of polydextrose powder (total 32g of basic formula), 30g of patrinia herb, 30g of hairyvein agrimony, 10g of Chinese gall, 10g of white muscardine silkworm, 20g of Chinese yam, 20g of radix trichosanthis, 20g of poria cocos, 20g of medlar polysaccharide, 20g of gordon euryale seed, 20g of lotus seed, 20g of dried ginger, 15g of turmeric, 20g of rhodiola rosea, 30g of powder, 10g of ginseng, 20g of radix codonopsis pilosulae, 20g of astragalus root, 10g of rhizoma atractylodis, 10g of euonymus alatus, 10g of radix scrophulariae, 10g of Chinese wolfberry, 20g of radix scrophulariae, 10g of Chinese wolfberry, 10g of peach kernel, 10g of Chinese mugwort, 10g of Chinese wolfberry, etc.
Further effects will be described below in connection with specific cases.
1. Case for lady patient
1. Basic conditions before conditioning: name: zhang Yanping, sex: female, age: 66, occupation: retirement, marital: already, address: brief introduction of the condition in the region of the turbid south of Shenyang, liaoning province: diagnosis: type 2 diabetes; complications: hyperlipidemia, hypotension, hyperhomocysteinemia; complications: brain trauma; insomnia, anxiety disorders; medical history: 3 years, no allergic history; checking the condition during diagnosis: blood diabetes sugar: pre-meal blood glucose 12.5 mmole/liter, post-meal (2 hours) blood glucose 16.3 mmole/liter, urine glucose: none, glycosylated hemoglobin: 10.6, titanium c (insulin function) is not detailed; 2. blood pressure: 108/60;3. blood lipid 6 items: total cholesterol: normal, high density lipoprotein: normal, low density lipoprotein: higher, triglycerides: normal, 4. Uric acid: normal, 5. Homocysteine: 16.8%. The traditional treatment conditions are as follows: time of diagnosis: in early 2019, diabetes was diagnosed when hospitalized for treatment of brain trauma; the medicine consumption condition is as follows: beginning at the beginning of 2019, starting to inject the long-acting insulin liraglutide injection, injecting 12 international units daily, and taking metformin hydrochloride (glibenclamide) 0.5/tablet 1 time daily for treatment time: for 2 years; other medications: lipid-lowering drugs, blood-activating and stasis-removing traditional Chinese medicines; premenstrual symptoms: debilitation, obesity, occasional bitter taste in the mouth and dry throat, insomnia, difficulty in falling asleep, sometimes easy to wake, and excessive and clear thinking. Spontaneous perspiration, shortness of breath, hiccup, shortness of breath, anxiety, occasional vexation, dizziness after tiredness, cerebral distension, inability to eat cool food, frequent stools, loose stools originally, cold feeling below the knee; other symptoms: after sudden stunning of the brain in 2019, there was a surgery for sucking blood stasis by intracranial drilling.
2. The conditioning process comprises the following steps: 2.1 comprehensive treatment method: 30 g of the functional food with the prescription is taken for 1 time a day, and is taken with water, and the blood sugar is regulated and controlled by combining with a sugar-controlling diet, and insulin and hypoglycemic drugs are gradually reduced according to the blood sugar condition; 2.2 daily administration method: the breakfast is taken with 30 g of the functional food, 1 egg, 250 milk (or water), 4 black fungus slices, 5 g of olive oil, a small amount of dried shrimps and refined salt are added, and the breakfast is taken after steaming; 5 g of tartary buckwheat, 3 g of sorghum rice, 2 g of soybean, 3 g of gorgon fruit and 10 g of balsam pear are taken after being soaked in warm water for 5 or 10 hours (sour taste can be achieved by fermentation), and then the porridge is boiled for taking, and leaf vegetables and fish are arbitrarily selected; randomly selecting dinner, chicken, seafood and leaf vegetables; the food is cooked by selecting virgin, grade 2 or grade 3 soybean oil, or rapeseed oil. Nut snack: is prepared from walnut, pumpkin seed, sunflower seed, etc; the main food is 3 meals a day, wherein the main food is mainly selected from milk, meat, seafood, vegetables and high-quality fat; similarly, the method is used for conditioning every day; 2.3 diet taboo: the forbidden carbohydrate mainly comprises rice, flour and sugar, including sugar-containing food, beverage and sugar-oil mixed food. 2.4 in combination with nutritional therapy: taking nutrient supplements, astaxanthin, vitamin B group, lipoic acid, chromium element, vitamin A, vitamin E and vitamin C;2.5 homocysteinemia: vitamin B1, vitamin B2, vitamin B6, vitamin B12 (all of which are taken in the above amounts), folic acid. 2.6 description: 1. the diet during conditioning treatment can only be selected within the required range, and can not be eaten randomly; 2. the fat food can be properly added without carbohydrate, some fat meat is eaten according to proper proportion, olive oil, linseed oil, sesame paste and the like are properly added in vegetable, the carbohydrate (sugar) food is reduced or not used, and the fat food consumption is properly increased, so that the heat required by the body is ensured; 3. the beverage can drink tea water, white boiled water and forbidden carbonated beverage; 4. blood sugar does not reach the standard, and fruits are not eaten. Fruits with low glycemic index and low glycemic load are properly eaten after blood glucose is nearly normal, or before exercise;
3. The conditioning treatment course record: 3.1 Conditioning treatment 1 treatment course (30 days), using De Gu Lila Lupeptide insulin, the daily injection amount is reduced from 12 international units to 8 units (12 units daily for initial period of onset), the insulin dosage is reduced by 4 units every 30 days, and the hypoglycemic agent dosage is unchanged. Conditioning treatment results: the dosage of insulin is reduced, the original blood sugar is not increased or reduced, and the blood sugar is kept stable; 3.2 Conditioning 2 treatment courses (60 days), with De Gu Lila Lupeptide insulin, daily injection was reduced to 4 units, 4 units every 30 days, and the hypoglycemic agent dose was unchanged. Conditioning treatment results: gradually reducing the dosage of insulin, keeping the original blood sugar stable without rising and falling; 3.3 conditioning treatment for 6 courses (180 days), the des Gu Lila lupeptide insulin and the hypoglycemic agent metformin are all stopped, and the blood sugar is kept stable and basically reaches the standard;
4. conditioning treatment results: the conditioning treatment is carried out for half a year, insulin and hypoglycemic agents are completely stopped, and the medicine is tested by Shenyang gold-domain medical test on the day 13, 10 of 2022, and several main test indexes of diabetes are as follows: morning fasting blood glucose 6.8 mmoles/liter, 2 hours after meal 9.3 mmoles/liter, glycosylated hemoglobin: 6.4, normal, homocysteine: 11.3, normal, uric acid: 385, blood lipid 6: total cholesterol: 4.85, higher, high density lipoprotein: 1.06, normal, low density lipoprotein: 3.10, higher, triglycerides: 1.95, normal, apolipoprotein A1:1.42, apolipoprotein B:1.08, 6 blood fat levels basically reach the standard; its symptoms: bitter taste in mouth, dry throat, spontaneous perspiration, short breath, hiccup, short breath, anxiety, occasional vexation, dizziness after fatigue, cerebral distention, incapacitation of eating cool food, debilitation and other symptoms disappear, and the physical strength is full, the patient is loose, and the symptoms of cold feeling, insomnia, anxiety and the like below the knee are all improved.
2. Mr. Li patient case
1. Basic conditions before conditioning: name: li Fengyao, sex: male, age: 68, occupation: retirement, marital: already, address: brief introduction of the condition in the region of the turbid south of Shenyang, liaoning province: diagnosis: type II diabetes; complications: hyperlipidemia, hypertension, hyperuricemia, mild diabetic eye disease, dorsum of foot arterial thrombosis; complications: prostatic hyperplasia, cervical spondylosis and gastritis; 2. medical history: for 12 years, there was no history of allergy; checking the condition during diagnosis: results of examination at day 3, 4, 2010, at the hospital admission of the ninth person in Shenyang: blood diabetes sugar: pre-meal blood glucose 15.1 mmole/liter, post-meal (2 hours) blood glucose 25.6 mmole/liter, urine glucose: ++, ketone body: ++, glycosylated hemoglobin: 12.3, titanium c (insulin function) is not detailed; 2. blood pressure: 160/100;3. blood lipid 6 items: total cholesterol: 6.83 high, high density lipoprotein: 1.86, normal, low density lipoprotein: 4.71, higher, triglycerides: 3.0, higher, apolipoprotein B:1.34 high serum lipoprotein a:52, high, 4. Uric acid: 598 high, homocysteine: checking; previous treatment case 1. Time to confirm diagnosis: the diabetes is found and confirmed in Shenyang red cross hospital 3.3.2010; the medicine consumption condition is as follows: hospitalization for 3 months and 4 days in 2010 (Shenyang, ninth people's hospital), discharge for 3 months and 15 days, control blood sugar with insulin after returning home, daily injection of 38 units of insulin, early injection of 24 units, oral administration of 2 tablets of cabozhen, late injection of 14 units, oral administration of 1 tablet of metformin. The pancreatic stem cell transplantation operation is performed in the four-level central hospital in 2012 at 4 months, and the curative effect is poor; insulin and hypoglycemic agents have been injected from now on, treatment time: 11 years; 3. other medications: antihypertensive drug: irbesartan, lipid-lowering agent: pitavastatin, a traditional Chinese medicine for regulating spleen and stomach and promoting blood circulation to remove blood stasis. Previous treatment procedure: the 1 st round of test starts in 3 months of 2014, and mainly comprises probiotics and diet therapy; beginning in 2018 of 2 nd round of test, mainly diet therapy and traditional Chinese medicine; beginning in 12 months of trial 2021, dialectical diet conditioning, dialectical nutrient conditioning and dialectical traditional Chinese medicine conditioning, namely triple comprehensive therapy of diabetes; 4 th round of test 2022 starts in 4 months, and the low-carbon nutritional functional food is subjected to dialectical diet conditioning, dialectical nutrient conditioning and dialectical traditional Chinese medicine conditioning; existing basic symptoms: the eyes are unclear, the eyes are blurred for a long time such as reading books or watching television, and the upper eyelid edema (obvious in the morning). Eye flowers (300 degree flower mirror must be worn). When people eat spicy things (peppers) or drink hot soup each time, sticky phlegm, nasal discharge and sweat on the top of the head appear. When the weather is too cold, the nasal discharge is cleared. Snoring during sleeping and apnea phenomenon. Tooth marks are formed on the tongue, and when the tongue is bad breath and insulin is not used, the tongue is bitter (not dry) and the morning is heavy. The cooked wheaten food has serious heartburn, excessive gastric acid and water drinking, the baking soda is not relieved, the cooked wheaten food has heavier gastric acid, and the cooked wheaten food disappears after insulin is added. Gastritis is caused by long-term gastric acid, and frequent gastralgia is caused by eating cool food. Gingival bleeding, cervical vertebra pain of 40 years, clicking, severe stiffness, multiple lipoma (outside skin and meat) in the whole body, and many years. Aversion to cold, cold endings, such as limbs, ears and nose. Spontaneous perspiration, no matter what part of the body is in summer, can occur as long as the parts are close together. Bloody urine and essence blood after recovery after the activity in the morning when the hands get up, go to the doctor's college and the college of two and seven, and find no cause. The doctor considers that the prostate is hypertrophic. Two cystoscopes suggest that two blood vessels are thick in the bladder. The patients take the medicine for more than 1 month in Shenyang middle-aged hospitals, and are improved. Now, it is lightened, but not healed. Foam in urine (daily) and fatigue. Blood pressure is high, and blood pressure is increased due to excessive speaking, poor sleep and the like as long as people go out. The sitting time is slightly longer, the sacral and perineum positions are painful, and even the driving is painful in the city. The muscle soreness of the whole body can not be received when sitting for a long time. Diarrhea in severe cases, pain after diarrhea is relieved. As long as the blood sugar is high, small fire furuncles can be generated on the head, skin itch is generated all over when the head is heated, and the skin itch is heavy in summer, especially in the sun.
2. The conditioning process comprises the following steps: 3.1 comprehensive treatment method: 30 g of the functional food with the prescription is taken for 1 time a day, and is taken with water, and the blood sugar is regulated and controlled by combining with a sugar-controlling diet, and insulin and hypoglycemic drugs are gradually reduced according to the blood sugar condition; 3.2 daily administration method: the breakfast is taken with 30 g of the functional food, 1 egg, 250 milk (or water), 4 black fungus slices, 5 g of olive oil, a small amount of dried shrimps and refined salt are added, and the breakfast is taken after steaming; 5 g of tartary buckwheat, 3 g of sorghum rice, 2 g of soybean, 3 g of gorgon fruit and 10 g of balsam pear are taken after being soaked in warm water for 5 or 10 hours (sour taste can be achieved by fermentation), and then the porridge is boiled for taking, and leaf vegetables and fish are arbitrarily selected; randomly selecting dinner, chicken, seafood and leaf vegetables; the food is cooked by selecting virgin, grade 2 or grade 3 soybean oil, or rapeseed oil. Nut snack: walnut, pumpkin seed, peanut, sweet almond and the like; the main food is 3 meals a day, wherein the main food is mainly selected from milk, meat, seafood, vegetables and high-quality fat; similarly, the method is used for conditioning every day; 3.3 diet taboo: the forbidden carbohydrate mainly comprises rice, flour and sugar, including sugar-containing food, beverage and sugar-oil flour mixed food. 3.4 in combination with nutritional therapy: taking nutrient supplements, astaxanthin, vitamin B group, lipoic acid, chromium element, vitamin A, vitamin E and vitamin C;3.5 homocysteinemia: vitamin B1, vitamin B2, vitamin B6, vitamin B12 (all of which are taken in the above amounts), folic acid. 3.6 description: the diet during conditioning treatment can only be selected within the required range, and can not be eaten randomly; the fat food can be properly added without carbohydrate, some fat meat is eaten according to proper proportion, olive oil, linseed oil, sesame paste and the like are properly added in vegetable, the carbohydrate (sugar) food is reduced or not used, and the fat food consumption is properly increased, so that the heat required by the body is ensured; 3. the beverage can drink tea water, white boiled water and forbidden carbonated beverage; 4. blood sugar does not reach the standard, and fruits are not eaten. Fruits with low glycemic index and low glycemic load are properly eaten after blood glucose is nearly normal, or before exercise;
3. The conditioning treatment course record: 4.1 Conditioning treatment for 1 treatment course (30 days), wherein the daily injection amount is reduced from 38 international units to 34 units (38 units are injected at the highest day in the initial stage of onset), the insulin dosage is reduced by 4 units every 30 days, and the metformin daily 2 tablets are taken; the dosage of insulin is reduced, the original blood sugar is not increased or reduced, and the original blood sugar level is maintained; 4.2 Conditioning treatment for 2 treatment courses (60 days), using norbenazolin insulin, reducing daily injection amount to 30 units, reducing daily injection amount to 4 units every 30 days, and adding metformin daily 2 tablets; gradually reducing the dosage of insulin, keeping the original blood sugar level without rising and falling; 4.3 Conditioning for 3 treatment courses (90 days), using norbenazolin insulin, daily injection amount is reduced to 24 units, daily injection amount is reduced to 6 units every 30 days, and metformin daily 2 tablets are added; gradually reducing the dosage of insulin, keeping the original blood sugar level without rising and falling; 4.4 Conditioning treatment 4 treatment courses (120 days), with norbenazolin insulin, daily injection was reduced to 16 units, 8 units every 30 days, and only metformin daily 2 tablets were taken; gradually reducing the dosage of insulin, keeping the original blood sugar level without rising and falling; 4.5 Conditioning treatment for 5 treatment courses (150 days), using norbenazolin insulin, reducing daily injection amount to 6 units, reducing daily injection amount to 10 units every 30 days, and adding metformin daily 2 tablets; gradually reducing the dosage of insulin, keeping the original blood sugar level without rising and falling; 4.6 conditioning treatment 6 courses (180 days), complete inactivation of norbenazolin insulin, administration of metformin daily 2 tablets; the original blood sugar is not increased or decreased, and the original blood sugar level is maintained; 4.7 conditioning treatment for 12 courses of treatment (360 days), stopping the whole of the hypoglycemic agent metformin, keeping the blood sugar stable and ensuring that the blood sugar index basically reaches the standard;
4. Conditioning results: for half a year, the conditioning treatment is carried out, insulin and hypoglycemic agents are completely stopped, and the treatment is carried out for 18 days in 2022, and after examination by the Shenyang Zhong nan blue card listening rain wave clinic entrusted with Shenyang gold domain medical examination, several main examination indexes of diabetes are: morning fasting blood glucose 6.8 mmoles/liter, 2 hours after meal 9.3 mmoles/liter, glycosylated hemoglobin: 6.4, normal, homocysteine: 10.4, normal, uric acid: 415, blood lipid 6: total cholesterol: 6.9, higher, high density lipoprotein: 1.19, normal, low density lipoprotein: 4.97, higher, triglycerides: 1.48, normal, all others normal; 2023, 2 nd month, 2 days, the Shenyang-muddy-nan blue card listening rain-wave clinic entrusts Shenyang golden field medical examination institute to examine, several main examination indexes of diabetes: morning fasting blood glucose 6.7 mmoles/liter, 2 hours after meal 8.3 mmoles/liter, glycosylated hemoglobin: 6.3, normal, homocysteine (not examined), uric acid: 324, blood lipid 6: total cholesterol: 4.38, normal, high density lipoprotein: 1.38, normal, low density lipoprotein: 2.71, normal, triglycerides: 1.61, normal, other indices are all normal; the most important blood lipid index of the low-density lipoprotein cholesterol is reduced from 4.97 to 2.71, and the inspection shows that the invention has obvious effect and reliable curative effect. Its symptoms: debilitation, bitter taste, spontaneous perspiration, night sweat, blurred vision, inability to eat cool food, loose stool, itching eyes, dislocation (light) caused by vehicle clamping, and the like, and the symptoms of full physical strength, other diseases such as impotence, cold feeling, cold ending, cold hands and feet, and the like are all eliminated;
3. Mr. Song patient case
1. Basic conditions: name: song Wei, sex: age of men: 60, occupation: police, marital: already, address: the general introduction of the disease in Shenyang City of Liaoning: diagnosis: early stage of type 2 diabetes; complications: hyperlipidemia, hyperhomocysteinemia; complications: polyp of stomach and intestine, gastritis, frequent urination. Medical history: 2 years, no allergic history; checking the condition during diagnosis: blood diabetes sugar: pre-meal blood glucose 8.95 mmole/liter, post-meal (2 hours) blood glucose 10.3 mmole/liter, urine glucose: none, glycosylated hemoglobin: 7.9, titanium c (insulin function) is not detailed; 2. blood pressure: 150/95;3. blood lipid 4: total cholesterol: 6.4, higher, high density lipoprotein (good cholesterol): 1.02 normal, low density lipoprotein: 3.64 higher, triglycerides: 3.58 is higher, 4. Uric acid: normal, 5. Homocysteine: checking; the traditional treatment conditions are as follows: time of diagnosis: early 2020, confirmed diabetes mellitus; the medicine consumption condition is as follows: at the beginning of 2020, metformin hydrochloride (glibenclamide) 0.5/tablet is taken 2 times daily, 1 time 1 tablet, and the treatment time is as follows: for 2 years; other medications: lipid-lowering and blood pressure-lowering drugs. Premenstrual symptoms: debilitation, occasional bitter taste, dry throat, excessive anxiety, occasional vexation, inability to eat uncooked and hard food, frequent stools, loose stools and frequent urination.
2. The conditioning process comprises the following steps: 2.1 comprehensive treatment method: 30 g of the functional food with the prescription is taken for 1 time a day, is taken with water, is combined with a sugar-control diet to regulate and control blood sugar, and simultaneously stops the hypoglycemic medicine for stopping the food; 2.2 daily administration method: the breakfast is taken with 30 g of the functional food, 1 egg, 250 milk (or water), 4 black fungus slices, 5 g of olive oil, a small amount of dried shrimps and refined salt are added, and the breakfast is taken after steaming; 5 g of tartary buckwheat, 3 g of sorghum rice, 2 g of soybean, 3 g of gorgon fruit and 10 g of balsam pear are taken after being soaked in warm water for 5 or 10 hours (sour taste can be achieved by fermentation), and then the porridge is boiled for taking, and leaf vegetables and fish are arbitrarily selected; randomly selecting dinner, chicken, seafood and leaf vegetables; the food is cooked by selecting virgin, grade 2 or grade 3 soybean oil, or rapeseed oil. Nut snack: is prepared from walnut, pumpkin seed, sunflower seed, etc; the main food is 3 meals a day, wherein the main food is mainly selected from milk, meat, seafood, vegetables and high-quality fat; similarly, the method is used for conditioning every day; 2.3 diet taboo: the forbidden carbohydrate mainly comprises rice, flour and sugar, including sugar-containing food, beverage and sugar-oil mixed food. 2.4 in combination with nutritional therapy: taking nutrient supplements, astaxanthin, vitamin B group, lipoic acid, chromium element, vitamin A, vitamin E and vitamin C;2.5 homocysteinemia: vitamin B1, vitamin B2, vitamin B6, vitamin B12 (all of which are taken in the above amounts), folic acid. 2.6 description: 1. the diet during conditioning treatment can only be selected within the required range, and can not be eaten randomly; 2. the fat food can be properly added without carbohydrate, some fat meat is eaten according to proper proportion, olive oil, linseed oil, sesame paste and the like are properly added in vegetable, the carbohydrate (sugar) food is reduced or not used, and the fat food consumption is properly increased, so that the heat required by the body is ensured; 3. the beverage can drink tea water, white boiled water and forbidden carbonated beverage; 4. blood sugar does not reach the standard, and fruits are not eaten. Fruits with low glycemic index and low glycemic load are properly eaten after blood glucose is nearly normal, or before exercise;
3. The conditioning treatment course record: 3.1 Conditioning treatment 1 treatment course (30 days), the hypoglycemic agent, guhuatai, is reduced to 1 tablet per day; conditioning treatment results: the dosage of hypoglycemic drugs is reduced, the original blood sugar is not increased or reduced, and the blood sugar is kept stable; 3.2 Conditioning for 2 treatment courses (60 days), stopping the hypoglycemic agent for the treatment of the heart disease; conditioning treatment results: the hypoglycemic agent is stopped, the original blood sugar is not increased or reduced, and the blood sugar is kept stable; 3.3 conditioning treatment for 3 treatment courses (90 days), without any hypoglycemic agent, the blood sugar is kept stable and basically reaches the standard;
4. conditioning results: the conditioning treatment is carried out for half a year, the hypoglycemic drugs are completely stopped, and the medicine is tested by Shenyang gold-domain medical test on days 10 and 13 of 2022, and several main inspection indexes of diabetes are as follows: the fasting blood glucose in the morning is 7.92 mmol/L, 1.03 percent drop, and the postprandial time is 9.3 mmol/L, 1 percent drop; glycosylated hemoglobin: 6.4, 1.5 percent decrease, homocysteine: without examination, uric acid: 385, blood lipid 4: total cholesterol: 5.53, 0.87 percent decrease, high density lipoprotein (good cholesterol): 1.27, 0.25 percent rise, low density lipoprotein: 2.83, 0.81 percent drop, triglyceride: 3.49, 0.09 percent drop; its symptoms: symptoms such as bitter taste, dry throat, spontaneous perspiration, debilitation and the like are all eliminated, and symptoms such as vigorous physical strength, loose stool, cold feeling below the knee, frequent urination, anxiety and the like are improved.
4. King lady patient case
1. Basic conditions before conditioning: name: wang Sumei, sex: age of female: 65, occupation: reporter, marital: already, address: general introduction to the disease in Shenyang City Shen Heou: diagnosis: type 2 diabetes; complications: coronary heart disease, hyperlipidemia; complications: hypotension; medical history: 2 years, no allergic history; checking the condition during diagnosis: blood diabetes sugar: morning fasting blood glucose 7.9 mmole/liter, postprandial (2 hours) blood glucose 11.5 mmole/liter, urine glucose: none, glycosylated hemoglobin: 7.9, titanium c (insulin function) is not detailed; 2. blood pressure: 150/95;3. blood lipid 4: total cholesterol: 7.27, higher, high density lipoprotein (good cholesterol): 1.40 normal, low density lipoprotein: higher 4.19, triglycerides: 1.73 is higher, 4. Uric acid: normal, 5. Homocysteine: checking; the traditional treatment conditions are as follows: time of diagnosis: early 2020, confirmed diabetes mellitus; the medicine consumption condition is as follows: at the beginning of 2020, metformin hydrochloride (glibenclamide) 0.5/tablet is taken 2 times daily, 1 time 1 tablet, and the treatment time is as follows: for 2 years; other medications: lipid-lowering medicine, coronary-expanding medicine and Chinese medicine; premenstrual symptoms: debilitation, chest distress, short breath, occasional bitter taste, itching throughout the body, anxiety, preference for eating spicy food, constipation;
2. The conditioning process comprises the following steps: 2.1 comprehensive treatment method: 30 g of the functional food with the prescription is taken for 1 time a day, is taken with water, is combined with a sugar-control diet to regulate and control blood sugar, and simultaneously reduces the dosage of the hypoglycemic medicine, namely, the granulization; 2.2 daily administration method: the breakfast is taken with 30 g of the functional food, 1 egg, 250 milk (or water), 4 black fungus slices, 5 g of olive oil, a small amount of dried shrimps and refined salt are added, and the breakfast is taken after steaming; 5 g of tartary buckwheat, 3 g of sorghum rice, 2 g of soybean, 3 g of gorgon fruit and 10 g of balsam pear are taken after being soaked in warm water for 5 or 10 hours (sour taste can be achieved by fermentation), and then the porridge is boiled for taking, and leaf vegetables and fish are arbitrarily selected; randomly selecting dinner, chicken, seafood and leaf vegetables; the food is cooked by selecting virgin, grade 2 or grade 3 soybean oil, or rapeseed oil. Nut snack: is prepared from walnut, pumpkin seed, sunflower seed, etc; the main food is 3 meals a day, wherein the main food is mainly selected from milk, meat, seafood, vegetables and high-quality fat; similarly, the method is used for conditioning every day; 2.3 diet taboo: the forbidden carbohydrate mainly comprises rice, flour and sugar, including sugar-containing food, beverage and sugar-oil mixed food. 2.4 in combination with nutritional therapy: taking nutrient supplements, astaxanthin, vitamin B group, lipoic acid, chromium element, vitamin A, vitamin E and vitamin C;2.5 homocysteinemia: vitamin B1, vitamin B2, vitamin B6, vitamin B12 (all of which are taken in the above amounts), folic acid. 2.6 description: 1. the diet during conditioning treatment can only be selected within the required range, and can not be eaten randomly; 2. the fat food can be properly added without carbohydrate, some fat meat is eaten according to proper proportion, olive oil, linseed oil, sesame paste and the like are properly added in vegetable, the carbohydrate (sugar) food is reduced or not used, and the fat food consumption is properly increased, so that the heat required by the body is ensured; 3. the beverage can drink tea water, white boiled water and forbidden carbonated beverage; 4. blood sugar does not reach the standard, and fruits are not eaten. Fruits with low glycemic index and low glycemic load are properly eaten after blood glucose is nearly normal, or before exercise;
3. The conditioning treatment course record: 3.1 Conditioning treatment 1 treatment course (30 days), the hypoglycemic agent, guhuatai, is reduced to 1 tablet per day; conditioning treatment results: the dosage of hypoglycemic drugs is reduced, the original blood sugar is not increased or reduced, and the blood sugar is kept stable; 3.2 Conditioning for 2 treatment courses (60 days), stopping the hypoglycemic agent for the treatment of the heart disease; conditioning treatment results: the hypoglycemic agent is stopped, the original blood sugar is not increased or reduced, and the blood sugar is kept stable; coronary heart disease is also improved; 3.3 conditioning treatment for 3 treatment courses (90 days), without any hypoglycemic agent, the blood sugar is kept stable and basically reaches the standard; the blood fat is reduced to some extent; chest distress and shortness of breath are improved;
4. conditioning results: the conditioning treatment is carried out for half a year, the hypoglycemic drugs are completely stopped, and the medicine is tested by Shenyang gold-domain medical test on days 10 and 13 of 2022, and several main inspection indexes of diabetes are as follows: 6.8 mmole/L of fasting blood glucose in the morning, 1.1 percent drop, 9.8 mmole/L of postprandial 2 hours, 1.7 percent drop; glycosylated hemoglobin: 5.8, 2.1 percent decrease, homocysteine: without examination, uric acid: 385, blood lipid 4: total cholesterol: 4.96, 2.31 percent drop, high density lipoprotein (good cholesterol): 1.42, 0.02 percentage points rise, low density lipoprotein: 2.89, 1.3 percent drop, triglyceride: 1.78, 0.05 percent rise; its symptoms: symptoms such as hypodynamia, chest distress, short breath, occasional bitter taste, itching of the whole body, anxiety, constipation and the like are relieved, and the physical strength is full.
The conditioning test results of the patient cases are all obtained by the test of Shenyang gold domain medical test by Shenyang listening Yulan blue card clinic.
The following is a statistical table of the patient's effects:
low-carbon nutritional functional food patient use effect test statistical table
Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
It will be understood that the invention is not limited to what has been described above and that various modifications and changes may be made without departing from the scope thereof. The scope of the invention is limited only by the appended claims.
Claims (7)
1. A basic formula of a low-carbon nutritional functional food for comprehensively regulating blood sugar, which is characterized by comprising the following raw materials in parts by weight: 1-18 g of balsam pear extract, 1-12 g of laminarin, 1-12 g of astragalus extract, 1-12 g of medlar extract, 1-12 g of purified konjak powder, 1-18 g of pseudo-ginseng decoction piece raw powder, 1-18 g of American ginseng decoction piece raw powder, 1-18 g of poria cocos decoction piece raw powder, 1-18 g of fried cucumber seed raw powder, 1-12 g of fried semen cassiae decoction piece raw powder, 1-6 g of calcined mother-of-pearl decoction piece raw powder, 1-12 g of instant yeast powder and 2-18 g of polydextrose powder.
2. The base formula of a low carbon nutritional functional food for integrated glycemic control according to claim 1, characterized in that the base formula comprises the following raw materials by weight: 3 g of balsam pear extract, 2 g of laminarin, 2 g of astragalus extract, 2 g of medlar extract, 3 g of purified konjaku flour, 3 g of pseudo-ginseng decoction piece raw powder, 3 g of American ginseng decoction piece raw powder, 3 g of poria cocos decoction piece raw powder, 3 g of stir-fried cucumber seed raw powder, 2 g of stir-fried semen cassiae decoction piece raw powder, 1 g of calcined mother-of-pearl decoction piece raw powder, 2 g of instant yeast powder and 3 g of polydextrose powder.
3. The base formula of a low carbon nutritional functional food for integrated glycemic control according to claim 1 or 2, characterized in that the base formula further comprises the following raw materials by weight: 3-15 g of edible vegetable oil and/or 0.5 g of refined salt;
wherein the edible vegetable oil is olive oil, linseed oil or chia seed oil.
4. A low-carbon nutritional functional food for comprehensively regulating blood sugar, which is characterized by comprising any one of basic formulas and one or more of nutritional supplements, dietary therapy compositions, coarse cereal compositions, health-care products and traditional Chinese medicine decoction pieces according to the claims 1-3;
The nutritional supplement is one or more of astaxanthin or anthocyanin soft capsules 1 granule, B vitamin tablet 1 tablet, lipoic acid soft capsule 1 granule, chromium yeast soft capsule 1 granule, vitamin A soft capsule or multidimensional element 1 granule, vitamin E soft capsule 1 granule, vitamin C tablet 1 tablet, magnesium element tablet 1 tablet, zinc element tablet 1 tablet, vitamin D3 tablet 1 tablet and deep sea fish oil soft capsule 1 granule;
the dietetic composition consists of 250 milliliters of pure milk or warm water, 4-6 pieces of black fungus, 20-30g of walnut, 1 egg, 3g of dried small shrimps and 2g of refined salt; or comprises Chinese cabbage 80g, herba Zosterae Marinae 50g, bean curd 60g, rhizoma Zingiberis recens 3 pieces, flavoring and refined salt; or comprises undaria pinnatifida 60g, cabbage 100g, streaky pork 50g, flavoring and refined salt; or consists of 50g of tricholoma matsutake, 100g of green pepper, seasonings and refined salt; or 60g of coprinus comatus, 100g of chicken, seasoning and refined salt; or consists of kidney bean 100g and pork 80 g;
the coarse cereal composition comprises 50g of whole tartary buckwheat, 20g of sorghum rice, 10g of soybean or white kidney bean, 10g of peanut, 3g of black sesame and 3g of flaxseed or chia seed; or 50g of tartary buckwheat, 10g of gorgon fruit, 10g of lotus seed, 10g of oat, 10g of brown rice and 10g of quinoa; or comprises Coicis semen 100g, semen Phaseoli 30g, fructus Benincasae 100g and radix Polygoni Multiflori rhizoma Dioscoreae 50 g;
The health care product is one or more of black fungus extract 5g, ginseng extract 3g, chinese yam extract 5g, oyster peptide extract 5g, hawthorn polysaccharide 5g, hirudin 3g, ganoderan 5g, white kidney bean extract 5g, tagatose 5g, arabinose 5g, propolis 5g or blood sugar balance tablet 1;
the traditional Chinese medicine decoction pieces are one or more of 20g of hairyvein agrimony, 30g of herba patriniae, 20g of discolor cinquefoil herb, 10g of Chinese gall, 5g of white muscardine silkworm, 10g of Chinese yam, 10g of gorgon fruit, 10g of lotus seed, 5g of dried ginger, 5g of bunge cherry seed, 5g of peach seed, 10g of medlar, 5g of turmeric, 10g of rhodiola root-tuber powder, 10g of kudzuvine root powder, 5g of ginseng, 5g of pseudostellaria root, 5g of rhizoma atractylodis, 10g of winged euonymus twig, 10g of diverse wormwood herb, 10g of figwort root, 10g of cortex lycii radicis, 10g of astragalus mongholicus, 10g of lucid ganoderma, 3g of scented tea and 3g of green tea.
5. The low carbon nutritional functional food for integrated glycemic control of claim 4 wherein when the food is comprised of a base formula and a nutritional supplement, the base formula is 95-99 grams by weight and the nutritional supplement is 1-5 grams;
when the food consists of a basic formula and a dietary therapy composition, the basic formula is 20-30 g by weight, and the dietary therapy composition is 30-70 g by weight;
When the food consists of a basic formula and a coarse cereal composition, the basic formula is 30-50 g, and the coarse cereal composition is 50-70 g;
when the food consists of a basic formula and a health-care product, the basic formula is 30-50 g and the health-care product is 50-70 g by weight;
when the food consists of a basic formula and Chinese medicinal decoction pieces, the basic formula is 50-70 g by weight, and the Chinese medicinal decoction pieces are 30-50 g by weight.
6. The low-carbon nutritional functional food for comprehensively regulating blood sugar according to claim 4, wherein the specific preparation method of the coarse cereal composition is as follows: cleaning food materials, soaking coarse cereals in warm water, adding yeast powder, adding 100 ml warm water, sealing, placing in 25-30deg.C heat preservation environment, taking out after micro fermentation, and cooking in pressure cooker or common electric rice cooker to obtain dry rice or porridge.
7. The low-carbon functional food for comprehensively regulating blood sugar according to any one of claims 4 to 6, wherein the food is in the form of powder, granule, dry tablet, beverage or canned porridge for convenient eating.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310389155.8A CN116473234A (en) | 2023-04-13 | 2023-04-13 | Basic formula of low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar and functional food thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310389155.8A CN116473234A (en) | 2023-04-13 | 2023-04-13 | Basic formula of low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar and functional food thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116473234A true CN116473234A (en) | 2023-07-25 |
Family
ID=87216165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310389155.8A Pending CN116473234A (en) | 2023-04-13 | 2023-04-13 | Basic formula of low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar and functional food thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116473234A (en) |
-
2023
- 2023-04-13 CN CN202310389155.8A patent/CN116473234A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108112996B (en) | Nutritional composition for controlling hyperglycemia and improving immunity of type 2 diabetes mellitus people | |
CN103238897B (en) | Composite plant solid drink suitable for diabetic patients | |
CN101744170B (en) | Tartary buckwheat eight ingredient porridge suitable for patients with diabetes and preparing method thereof | |
CN105285952A (en) | Meal replacement powder with balanced nutrients and preparation method of meal replacement powder | |
CN110326780A (en) | A kind of nutritional meal replacement and preparation method thereof with function of blood sugar reduction | |
CN102224891B (en) | Sugar alcohol honey apple jam and preparation method thereof | |
CN102113648A (en) | Special dietary noodle applicable to people suffering from 'five-high' metabolic syndrome and preparation method thereof | |
CN104872504A (en) | Meal-replacing powder capable of replacing daily diet and having balanced nutrition and preparation method of meal-replacing powder | |
WO2011060585A1 (en) | Chewable tablets including essences of five-colour fruits and vegetables and preparative methods thereof | |
CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
WO2008014674A1 (en) | A nutritional and health-care edible potassium salt with wide purpose | |
CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
KR102396152B1 (en) | Easy-to-eat of Nutrition Balance Health Food | |
Yampolsky et al. | Apricot (lat. Prunus armeniaca Lin.) | |
CN104286273A (en) | Application of dendrobium candidum and tea leaf product thereof | |
CN103610144A (en) | Walnut powder with blood glucose reduction effect and preparation method thereof | |
CN108782679A (en) | A kind of weight-reducing intervention is dry and preparation method thereof for refreshment | |
CN104757689A (en) | Solid beverage with pine pollen, taurine and vitamins, and preparation method of the solid beverage | |
CN103750358B (en) | The healthcare beef that suitable three high crowds eat | |
CN110638038A (en) | Medical formula nutritional meal replacement powder for controlling hyperglycemia and preparation method thereof | |
CN104381869A (en) | Detoxifying and beautifying instant coarse grain product and preparation method thereof | |
CN116473234A (en) | Basic formula of low-carbon nutritional functional food for comprehensively regulating and controlling blood sugar and functional food thereof | |
CN107259318A (en) | A kind of nutritional health food | |
CN113842452A (en) | Medicine composition for treating diabetes and preparation method thereof | |
CN106035686A (en) | Super chenopodium quinoa willd health-preservation plant milk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |